Higher levels of antimitochondrial antibodies in patients with systemic lupus erythematosus are tied to a higher risk for ...
Telitacicept, a dual inhibitor of the cytokines B-lymphocyte stimulator and a proliferation-inducing ligand, showed efficacy ...
Zacks Investment Research on MSN
JNJ's nipocalimab meets goal in phase II study for systemic lupus
Johnson & Johnson JNJ announced that the phase IIb JASMINE study, which evaluated its pipeline candidate, nipocalimab, for ...
Fresh off of a European approval for a subcutaneous version of Saphnelo, AstraZeneca is doubling down on the benefits of the ...
Over 3.4 million people globally are affected by SLE, and it is one of the leading causes of death in young women in the US ...
Clinical Trials Arena on MSN
J&J’s Imaavy posts win in Phase II SLE trial
Imaavy will now progress to Phase III in SLE, though it will face strong competition from SLE market leader, Benlysta, if ...
China: A prospective multicentre cohort study from China suggests that telitacicept, when used alongside standard of care ...
Johnson & Johnson (JNJ) shares are in focus after two pipeline updates: a Phase 2b win for nipocalimab in systemic lupus ...
Johnson & Johnson (NYSE: JNJ) today announced positive topline results from the Phase 2b JASMINE (NCT04882878) study of adults living with systemic lupus erythematosus (SLE) and the initiation of a ...
Low baseline 25 (OH)D levels are associated with higher mortality and cardiovascular event risks among patients with systemic lupus erythematosus (SLE), with evidence of a U-shaped relationship ...
Objectives To examine the association between social determinants of health (SDH) and outcomes in systemic lupus ...
In systemic lupus erythematosus, chronic spontaneous urticaria did not raise SLEDAI scores, but cylindruria, mucosal ulcers, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback